Another big pharmaceutical is retreating from the development of new antibiotics, highlighting concerns around the challenges facing this market.
Browsing: Drug Development
Small-molecule compounds designed to tag the cell surface of Gram-negative bacteria and trigger an immunological response have shown promise.
In top-line results from a Phase IIa study, Abivax has reported mixed data, although ABX464 did appear to reduce HIV DNA in blood and rectal samples at a higher dose.
The US FDA has approved Zemdri for use in adults with complicated urinary tract infections; however, the agency has also issued a response for bloodstream infections noting there isn’t substantial evidence of Zemdri’s effectiveness.
After completing a strategic review, Allergan plans to sell its women’s health and infectious disease businesses, to focus on its four core areas of aesthetics, central nervous system diseases, eye care and gastrointestinal conditions.
The Global Antibiotic Research & Development Partnership (GARDP) – an interview with Jean-Pierre Paccaud
In our latest interview, we spoke to Jean-Pierre Paccaud, Director of Business Development & Corporate Strategy at GARDP, about the drug developer’s model and his thoughts on the wider field.
E. coli’s internal bomb – the toxin-antitoxin system – could be triggered to make bacteria turn on themselves, offering a new target for antimicrobial approaches in drug design.
Our sister site, MedChemNet, spoke to Joseph Hargan-Calvopiña, Program Manager at BIO Ventures for Global Health, to find out more about their work in global drug development for neglected tropical diseases.
We recently spoke about the ins and outs of funding and financing for antimicrobials with John Rex, who shares his thoughts on the issues underlying antibiotic development, the recent DRIVE-AB report, and where we might be 10 years in the future.
Promising data for dolutegravir and HIV combination therapy GS-9620 and PGT121: industry news round-up
Partnership announcements and promising trial data reported at the 2018 Conference on Retroviruses and Opportunistic Infections, take a look at our round-up of the latest industry headlines.